HCM
BCTXL

Heights Capital Management’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Heights Capital Management’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Sell
186,582
-113,418
-38% -$105K 0.03% 197
2026
Q1 		$300K Buy
+300,000
New +$318K 0.08% 152

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Heights Capital Management's BCTXL Position: Q2 2026 in Review

Heights Capital Management reduced its BriaCell Therapeutics Warrant (BCTXL) stake by 38% in Q2 2026, selling an estimated $105K and leaving 186,582 shares worth $149K. The position accounts for 0.03% of the portfolio, ranked #197.

Heights Capital Management first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $300K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Heights Capital Management held 186,582 shares of BriaCell Therapeutics Warrant worth $149K as of Q2 2026.
  • Heights Capital Management sold 113,418 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $105K.
  • BriaCell Therapeutics Warrant made up 0.03% of Heights Capital Management's portfolio in Q2 2026, its #197 holding.
  • Heights Capital Management first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Heights Capital Management's BriaCell Therapeutics Warrant position peaked at $300K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.